Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T Cells in R/R B-cell Acute Lymphoblastic Leukemia
NCT05309213Phase 2Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 2 trial of IM19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Immunochina Pharmaceuticals. Status: unknown.
02
Drugs
IM19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05309213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309213.